|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C1orf186 |
Gene summary for C1ORF186 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C1orf186 | Gene ID | 440712 |
| Gene name | regulator of hemoglobinization and erythroid cell expansion | |
| Gene Alias | C1orf186 | |
| Cytomap | 1q32.1 | |
| Gene Type | protein-coding | GO ID | GO:0002262 | UniProtAcc | Q6ZWK4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 440712 | C1orf186 | AEH-subject1 | Human | Endometrium | AEH | 7.83e-39 | -7.44e-01 | -0.3059 |
| 440712 | C1orf186 | AEH-subject2 | Human | Endometrium | AEH | 7.95e-31 | -7.44e-01 | -0.2525 |
| 440712 | C1orf186 | AEH-subject3 | Human | Endometrium | AEH | 5.67e-41 | -7.44e-01 | -0.2576 |
| 440712 | C1orf186 | AEH-subject4 | Human | Endometrium | AEH | 6.57e-24 | -7.44e-01 | -0.2657 |
| 440712 | C1orf186 | AEH-subject5 | Human | Endometrium | AEH | 5.67e-41 | -7.44e-01 | -0.2953 |
| 440712 | C1orf186 | EEC-subject1 | Human | Endometrium | EEC | 2.09e-41 | -7.44e-01 | -0.2682 |
| 440712 | C1orf186 | EEC-subject2 | Human | Endometrium | EEC | 4.11e-40 | -7.44e-01 | -0.2607 |
| 440712 | C1orf186 | EEC-subject3 | Human | Endometrium | EEC | 4.11e-40 | -7.44e-01 | -0.2525 |
| 440712 | C1orf186 | EEC-subject4 | Human | Endometrium | EEC | 2.82e-42 | -7.44e-01 | -0.2571 |
| 440712 | C1orf186 | EEC-subject5 | Human | Endometrium | EEC | 1.10e-39 | -7.44e-01 | -0.249 |
| 440712 | C1orf186 | GSM5276934 | Human | Endometrium | EEC | 2.94e-39 | -7.44e-01 | -0.0913 |
| 440712 | C1orf186 | GSM5276935 | Human | Endometrium | EEC | 2.08e-38 | -7.44e-01 | -0.123 |
| 440712 | C1orf186 | GSM5276937 | Human | Endometrium | EEC | 5.22e-29 | -7.44e-01 | -0.0897 |
| 440712 | C1orf186 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 2.90e-25 | -7.44e-01 | -0.1869 |
| 440712 | C1orf186 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 1.63e-22 | -7.44e-01 | -0.1875 |
| 440712 | C1orf186 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 3.81e-26 | -7.44e-01 | -0.1883 |
| 440712 | C1orf186 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 2.94e-39 | -7.44e-01 | -0.1934 |
| 440712 | C1orf186 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 7.83e-39 | -7.44e-01 | -0.1917 |
| 440712 | C1orf186 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 1.04e-33 | -7.44e-01 | -0.1916 |
| 440712 | C1orf186 | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 2.82e-42 | -7.44e-01 | -0.1269 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C1orf186 | SNV | Missense_Mutation | c.55N>G | p.Leu19Val | p.L19V | Q6ZWK4 | protein_coding | tolerated(0.06) | benign(0.056) | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| C1orf186 | SNV | Missense_Mutation | c.239N>G | p.Ser80Cys | p.S80C | Q6ZWK4 | protein_coding | tolerated(0.19) | benign(0.017) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| C1orf186 | SNV | Missense_Mutation | c.43N>A | p.Ala15Thr | p.A15T | Q6ZWK4 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A6-4107-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | 5 | SD | |
| C1orf186 | SNV | Missense_Mutation | c.449N>C | p.Lys150Thr | p.K150T | Q6ZWK4 | protein_coding | tolerated(0.11) | benign(0.111) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| C1orf186 | SNV | Missense_Mutation | c.256N>T | p.His86Tyr | p.H86Y | Q6ZWK4 | protein_coding | deleterious(0.02) | benign(0.001) | TCGA-G5-6235-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | PD | |
| C1orf186 | SNV | Missense_Mutation | novel | c.379N>A | p.Asp127Asn | p.D127N | Q6ZWK4 | protein_coding | tolerated(0.2) | benign(0.037) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C1orf186 | SNV | Missense_Mutation | c.140C>T | p.Ala47Val | p.A47V | Q6ZWK4 | protein_coding | tolerated(0.28) | benign(0.009) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| C1orf186 | SNV | Missense_Mutation | c.425T>C | p.Val142Ala | p.V142A | Q6ZWK4 | protein_coding | deleterious(0) | benign(0.412) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| C1orf186 | SNV | Missense_Mutation | novel | c.13G>A | p.Val5Ile | p.V5I | Q6ZWK4 | protein_coding | tolerated(0.17) | benign(0.062) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| C1orf186 | SNV | Missense_Mutation | c.101G>A | p.Ser34Asn | p.S34N | Q6ZWK4 | protein_coding | tolerated(0.07) | possibly_damaging(0.525) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |